Deliver Your News to the World

CybeRelease: (OTC: APPI) Gets New Target Price and Speculative Buy Rating


(CybeRelease, February 2, 2007) - Advanced Plant Pharmaceuticals (OTC BB: APPI) has been rated “Speculative Buy” with a target price of $0.06 by Beacon Equity Research Analyst Dr. Victor Sula.

The full report is available at
Anyone interested in receiving alerts regarding Advanced Plant Pharmaceuticals research should email with “APPI” in the subject line.

In the report, Dr. Sula writes, “Advanced Plant Pharmaceuticals, Inc. is shifting its business plan to focus on biofuels and renewable energy production and distribution. In Q4FY06, APPI announced an agreement to acquire World Health Energy (WHE), a renewable energy company focused on the development and production of alternative fuels. WHE plans to use cost-effective agricultural products both locally and from around the world to develop natural alternative fuels. The Company plans to build two biodiesel plants in the US and is in the process of securing financing for their construction.”

“According to Clean Edge research, the global biofuels market will grow from $15.7 billion in 2005 to $52.5 billion by 2015. Meanwhile, Emerging Markets Online forecasts US biodiesel consumption will grow to 750 million gallons by the end of 2007. Moreover, the US biodiesel market should grow significantly to match the consumption levels of European counterparts. Total biodiesel sales in the US amounted to less than 0.5% of all petro-diesel on-road consumption in 2005.”

To read the complete release, go to

For a Free Newsletter and more information, go to

CybeRelease Gainers are Seattle Genetics, Inc. (Nasdaq: SGEN), Sangamo BioSciences, Inc. (Nasdaq: SGMO), Allos Therapeutics, Inc. (Nasdaq: ALTH), Aviza Technology, Inc. (Nasdaq: AVZA), Nymox Pharmaceutical Corporation (Nasdaq: NYMX), Rochester Medical Corporation (Nasdaq: ROCM), Langer Inc. (Nasdaq: GAIT) and Secure Computing Corporation (Nasdaq: SCUR).

CybeRelease Decliners are Mentor Graphics Corporation (Nasdaq: MENT), Bookham, Inc. (Nasdaq: BKHM), Illumina, Inc. (Nasdaq: ILMN), Angiotech Pharmaceuticals, Inc. (Nasdaq: ANPI), Ionatron, Inc. (Nasdaq: IOTN), Sigmatel, Inc. (Nasdaq: SGTL), Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Digene Corporation (Nasdaq: DIGE).
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid CybeRelease $500.00 for the publication of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation and do no trading of any kind.


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.